US › Healthcare

Gain Therapeutics Inc (GANX)

US · Healthcare · Biotechnology

$1.76+0.57%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-5.6M
Profit YoY
-23.8%
EPS
$-0.13
EPS estimate
$-0.14

EPS came in at -0.13 against a street estimate of -0.14 — a beat of 7.1%.

Key statistics

Market cap
$71.7M
Forward P/E
0.0
P/B
5.13
Book value
$0.33
EPS (TTM)
$-0.58
52-week high
$4.34
52-week low
$1.43
50-day MA
$1.79
200-day MA
$2.19
Beta
0.16

Analyst view

Analysts rate Gain Therapeutics Inc a buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $7.20.

Shareholding

Insiders
2.29%
Institutions
19.36%

Largest institutional holders

FundStake
Marshall Wace Asset Management Ltd4.15%
Potomac Capital Management, Inc.2.36%
JONES FINANCIAL COMPANIES LLLP1.48%
CAMBRIDGE Invest RESEARCH ADVISORS, INC.1.33%
Geode Capital Management, LLC1.05%
Susquehanna International Group, LLP1.01%
Vanguard Capital Management, LLC0.94%
GSA Capital Partners LLP0.73%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Gain Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.